Hemab Therapeutics Holdings, Inc. (Ticker: COAG US) is an American clinical-stage biotech company focused on developing subcutaneous treatments for rare blood coagulation disorders. Hemab Therapeutics Holdings plans to list on the NASDAQ on May 1, 2026, planning to offer 11.76 million shares at a price range of $16.00 to $18.00, raising approximately $200 million at the midpoint of the range.

The Delaware-incorporated pharmaceutical company, founded in 2020, is developing its most advanced drug candidate, sutacimig, also known as HMB-001. The treatment has completed Phase 2 clinical trials and is reportedly ready to move into Phase 3 testing for Glanzmann thrombasthenia, a rare bleeding disorder. It is also in Phase 2 testing for Factor VII deficiency, another condition that affects the blood’s ability to clot. According to the prospectus, the company’s second drug candidate, HMB-002, is currently in Phase 1/2 trials for Von Willebrand Disease, a more common inherited bleeding disorder. The company does not yet generate revenue and reported a net loss of $63.91 million for the year ended December 31, 2025. Goldman Sachs, Jefferies, and Evercore ISI are serving as joint managers for the offering.